Trilafon

Depression, Generalized Anxiety Disorder, Schizophrenia + 8 more

Treatment

12 FDA approvals

20 Active Studies for Trilafon

What is Trilafon

Perphenazine

The Generic name of this drug

Treatment Summary

A medication used to treat mental health disorders, similar to the effects of chlorpromazine.

Perphenazine

is the brand name

image of different drug pills on a surface

Trilafon Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Perphenazine

Perphenazine

1987

153

Approved as Treatment by the FDA

Perphenazine, also known as Perphenazine, is approved by the FDA for 12 uses like Anxiety and Generalized Anxiety Disorder .

Anxiety

Used to treat severe Anxiety in combination with Amitriptyline

Generalized Anxiety Disorder

Used to treat Anxiety in combination with Amitriptyline

Mental Depression

Used to treat moderate Depressed mood in combination with Amitriptyline

Depression

Used to treat Depression in combination with Amitriptyline

Mental Depression

Used to treat severe Depressed mood in combination with Amitriptyline

severe Nausea and vomiting

moderate Anxiety

Used to treat moderate Anxiety in combination with Amitriptyline

Schizophrenia

Helps manage Schizophrenia

Chronic Physical Illness

Used to treat Chronic Physical Illness in combination with Amitriptyline

Nausea

severe agitation

Used to treat severe agitation in combination with Amitriptyline

moderate Agitation

Used to treat moderate Agitation in combination with Amitriptyline

Effectiveness

How Trilafon Affects Patients

Perphenazine is a powerful medication used to treat psychiatric disorders. It belongs to a class of drugs called phenothiazines, which block the chemical dopamine in the brain. Perphenazine is 10-15 times stronger than other phenothiazine drugs and is just as effective as haloperidol in treating symptoms, but may cause similar early and late side effects.

How Trilafon works in the body

Perphenazine works by blocking the activity of dopamine receptors, which are responsible for sending signals to the vomiting center in the brain. It also binds to alpha-adrenergic receptors and stops them from sending messages that could lead to nausea and vomiting.

When to interrupt dosage

The prescribed measure of Trilafon is contingent upon the diagnosed ailment, including Generalized Anxiety Disorder, moderate Agitation and Depression. The amount of dosage is contingent upon the administration technique (e.g. Syrup - Oral or Tablet, sugar coated - Oral) outlined in the accompanying table.

Condition

Dosage

Administration

Depression

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Nausea

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Anxiety

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Chronic Physical Illness

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

moderate Anxiety

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

moderate Agitation

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Mental Depression

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Mental Depression

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Generalized Anxiety Disorder

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Schizophrenia

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

severe agitation

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Warnings

Trilafon Contraindications

Condition

Risk Level

Notes

large dose of CNS depressants

Do Not Combine

Brain Injuries

Do Not Combine

Liver Damage

Do Not Combine

Coma

Do Not Combine

Disease

Do Not Combine

greatly obtunded patients

Do Not Combine

Bone Marrow

Do Not Combine

There are 20 known major drug interactions with Trilafon.

Common Trilafon Drug Interactions

Drug Name

Risk Level

Description

Amisulpride

Major

Perphenazine may increase the antipsychotic activities of Amisulpride.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Perphenazine.

Azelastine

Major

Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Dacomitinib

Major

The metabolism of Dacomitinib can be decreased when combined with Perphenazine.

Deutetrabenazine

Major

The risk or severity of adverse effects can be increased when Perphenazine is combined with Deutetrabenazine.

Trilafon Toxicity & Overdose Risk

Signs of an overdose of this drug include confusion and unconsciousness, and children may have seizures. It may take up to 48 hours for symptoms to become noticeable. Tests in rats and mice show that the lowest toxic dose is 318 mg/kg and 64 mg/kg, respectively.

image of a doctor in a lab doing drug, clinical research

Trilafon Novel Uses: Which Conditions Have a Clinical Trial Featuring Trilafon?

At present, 985 active clinical trials are investigating the potential of Trilafon to alleviate moderate Agitation, Anxiety and Nausea.

Condition

Clinical Trials

Trial Phases

Generalized Anxiety Disorder

181 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 4, Phase 1, Phase 3

Schizophrenia

97 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2

moderate Anxiety

0 Actively Recruiting

Nausea

0 Actively Recruiting

Anxiety

0 Actively Recruiting

moderate Agitation

0 Actively Recruiting

Chronic Physical Illness

1 Actively Recruiting

Not Applicable

severe agitation

0 Actively Recruiting

Depression

304 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Mental Depression

0 Actively Recruiting

Mental Depression

0 Actively Recruiting

Trilafon Reviews: What are patients saying about Trilafon?

5

Patient Review

9/25/2009

Trilafon for Mental Disorder with Loss of Normal Personality & Reality

TARDIVE DYSKINESIA

5

Patient Review

3/24/2010

Trilafon for Schizophrenia

I've tried a lot of different antipsychotics, and this is the first one that's both effective and doesn't have too many side effects.

5

Patient Review

11/26/2010

Trilafon for Schizophrenia

I've tried other medications in the same class as Trilafon, and this one is by far the most effective with the least amount of side effects.

4.7

Patient Review

5/7/2010

Trilafon for Mental Disorder with Loss of Normal Personality & Reality

I have bipolar disorder, ADHD, and severe anxiety disorder. I've been on Trilafon for a little while now and it's really helped to stabilize my moods. Much better than any other medication I've tried in the past.

4.7

Patient Review

4/10/2010

Trilafon for Mental Disorder with Loss of Normal Personality & Reality

I initially forgot to take this medication, but I was really pleased with how it curbed my appetite. I didn't feel the need to overeat anymore.

4

Patient Review

7/14/2010

Trilafon for Schizophrenia

I felt more focused and energetic, with fewer racing thoughts.

4

Patient Review

6/2/2009

Trilafon for Schizophrenia

3.7

Patient Review

5/14/2013

Trilafon for Schizophrenia

This medication was highly effective at removing my positive symptoms of schizophrenia. However, I developed abnormal mouth and tongue movements as a result. These movements have continued even after going off the medication, which has been since January. Therefore, I would not recommend this drug to anyone.

2.3

Patient Review

9/29/2012

Trilafon for Mental Disorder with Loss of Normal Personality & Reality

I was prescribed this medication after being misdiagnosed while in foster care. Even though it's been three years since I stopped taking the medicine, I continue to suffer from a variety of side effects, including sun sensitivity, irregular periods, an irregular heartbeat, sexual problems and eye twitches.

1

Patient Review

2/15/2012

Trilafon for Mental Disorder with Loss of Normal Personality & Reality

This treatment made me feel really out of it and not in a good way.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about trilafon

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does perphenazine do to your brain?

"Perphenazine is a type of medication known as a conventional antipsychotic. It works by reducing abnormal excitement in the brain."

Answered by AI

How long does it take for Trilafon to work?

"It may take as much as 4-6 weeks of regular use to see the full benefit of the medication, even though you may notice some effects soon after starting."

Answered by AI

Is Trilafon still available?

"The drug Trilafon is no longer being manufactured in the United States, but similar drugs may still be available. Trilafon was an antipsychotic drug used to treat schizophrenia. It belonged to a class of drugs called phenothiazines."

Answered by AI

What is Trilafon used for?

"Aripiprazole works by helping to restore the balance of certain natural substances (neurotransmitters) in the brain.

Aripiprazole is a medication used to treat certain mental disorders such as schizophrenia and bipolar disorder. This medicine helps the patient to think more clearly and take part in everyday life. It can reduce aggressive behavior and the desire to hurt oneself or others. Aripiprazole works by restoring the balance of certain neurotransmitters in the brain."

Answered by AI

Clinical Trials for Trilafon

Image of Northwestern University in Evanston, United States.

Sleep and Dreaming Practices for Anxiety

18+
All Sexes
Evanston, IL

People spend approximately one-third of their lives asleep, yet sleep is often underused as an opportunity to support psychological well-being. Contemplative traditions, including Tibetan Dream Yoga, have developed practices that use waking imagination and lucid dreaming to explore perception, awareness, and habitual patterns of thinking. Recent advances in sleep monitoring, dream communication, and lucid dream induction now make it possible to study these practices using scientific methods. This study is a randomized controlled trial designed to examine the feasibility and effects of a Dream-Yoga-inspired intervention compared with an active control condition. The intervention combines waking and dreaming practices that are adapted for individuals without prior experience and delivered using virtual reality-based training and home sleep technology. The program is designed to be scalable and culturally neutral, without requiring prior knowledge of contemplative or religious traditions. The primary goals of the study are to characterize sleep and waking neurophysiology associated with Dream-Yoga-inspired practices and to evaluate whether participation is associated with changes in sleep-related brain activity and cognitive processes. Outcomes include measures of lucid dreaming, sleep physiology, and waking cognitive and perceptual processes. Anxiety will be assessed as an exploratory outcome to examine whether participation may be associated with changes in emotional experience. This study is not designed to provide treatment for anxiety or other clinical conditions. Results from this study will help inform the development of scalable sleep-based mental training approaches and guide future research on the use of dreaming and sleep practices to support psychological health and well-being

Phase < 1
Waitlist Available

Northwestern University (+1 Sites)

Image of University of Michigan in Ann Arbor, United States.

Virtual Reality for Depression in Multiple Sclerosis

18+
All Sexes
Ann Arbor, MI

This trial explores the use of immersive virtual reality (VR) nature-based experiences as a supplementary treatment for depression in individuals with progressive multiple sclerosis (MS). This study will evaluate the feasibility and efficacy of at-home VR deployment using the Apple Vision Pro, an advanced device that offers enhanced resolution, immersion, and usability compared to earlier VR systems. The study hypotheses include: * The integration of VR nature-based experiences with standard care will be feasible, acceptable, and will result in greater reductions in depressive symptoms compared to standard care or VR-only interventions. * The integration of VR nature-based experiences with standard care will result in greater reductions in stress and anxiety, better sleep, less insomnia, and improved fatigue compared to standard care alone or VR-only interventions.

Recruiting
Has No Placebo

University of Michigan

Hala Darwish, PhD

Apple Inc.

Have you considered Trilafon clinical trials?

We made a collection of clinical trials featuring Trilafon, we think they might fit your search criteria.
Go to Trials
Image of Liao Lab at UCSF in San Francisco, United States.

Audio-Based Therapy for Anxiety in Psoriasis

18+
All Sexes
San Francisco, CA

Anxiety in psoriasis is associated with impaired quality of life, and the prevalence of anxiety symptoms in psoriatic populations is approximately 34% and anxiety disorders up to 16%. Many experts recommend routine screening, referral, and interventions for anxiety in psoriasis; however, many barriers inhibit access to mental health resources and proper management. To our knowledge, there is a lack of easily accessible interventions that manage anxiety. Audio-based therapy offers convenient and effective interventions that show reduced anxiety in published, randomized studies and is a promising management for psoriasis patients. This study will evaluate the effects of audio therapy in patients with psoriasis and measure changes in overall symptoms.

Waitlist Available
Behavior

Liao Lab at UCSF

Wilson Liao, MD

Image of Medical University of South Carolina (MUSC), Brain Stimulation Laboratory Institute of Psychiatry in Charleston, United States.

Mindfulness Training for Depression

18 - 70
All Sexes
Charleston, SC

This NIH-funded single-arm pilot tests the feasibility, acceptability, and preliminary effects of embedding brief guided mindfulness practice (via the Healthy Minds smartphone app) into the inter-session intervals of clinically administered accelerated intermittent theta-burst stimulation (aiTBS) for major depressive disorder (MDD). Participants receive aiTBS as standard clinical care at MUSC; the research intervention is daily guided mindfulness practice during the aiTBS course. Outcomes include feasibility/acceptability, changes in state mindfulness and hedonic tone (Day 0 to Day 5), perceived ease of meditation, trait mindfulness at 4 and 12 weeks, and durability of antidepressant response (PHQ-9) at 4 and 12 weeks.

Waitlist Available
Has No Placebo

Medical University of South Carolina (MUSC), Brain Stimulation Laboratory Institute of Psychiatry

Clayton Olash, MD

Have you considered Trilafon clinical trials?

We made a collection of clinical trials featuring Trilafon, we think they might fit your search criteria.
Go to Trials
Image of University of South Florida in Tampa, United States.

Web-Based Program for Parenting Stress

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to evaluate the feasibility, usability, and preliminary benefits of implementing ACT Together for parents of children with disabilities in pediatric outpatient clinics. ACT Together includes six self-paced, web-based modules and brief weekly one-on-one coaching sessions led by a trained occupational therapist. The program is based on acceptance and commitment therapy (ACT), which teaches practical skills to help people handle stress and difficult thoughts or feelings while taking steps toward what matters to them. The main questions this study aims to answer are: * Can parents and occupational therapists complete the study activities as planned (e.g., module completion, coaching sessions, and surveys)? * Is the program usable and acceptable/appropriate/feasible to implement in this setting? * Do parents show improvements in mental health and coping-related outcomes after participating in the program? * What are the experiences and perspectives of parents and therapists regarding the program? Parents as participants will: * Complete six self-paced web-based modules and brief weekly individual coaching sessions with a trained occupational therapist. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experiences and perspectives on the program. Occupational therapists as participants will: * Complete therapist training materials and deliver brief individual coaching sessions to parent participants, including completing a post-session checklist. * Complete brief online questionnaires before starting and after delivering the program. * Take part in one online interview about their experiences and perspectives on the program.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han, PhD

Image of Worcester Recovery Center and Hospital in Worcester, United States.

Changing Lives and Changing Outcomes-9 for Serious Mental Illness

18+
All Sexes
Worcester, MA

People with serious mental illness (depression, bipolar, and schizophrenia spectrum disorders) have high rates of repeated criminal legal involvement and psychiatric hospitalizations. Longstanding research shows that in addition to treating clients' symptoms of mental illness, targeting risk factors for legal involvement can help reduce their chances of future incarcerations. Because hospitals are becoming increasingly forensic, treatment programs that address both mental illness and risk factors for legal involvement may be especially helpful in a state hospital setting, like Worcester Recovery Center and Hospital (WRCH). This treatment study offers an adjunctive 9-session intervention, Changing Lives and Changing Outcomes-9 (CLCO-9), for patients at WRCH; this program is designed to help people with serious mental illness who are involved in the legal system increase their awareness of their mental health and reduce their chances of future legal involvement. The investigators are proposing a treatment study testing the use of the CLCO-9 group intervention with patients with serious mental illness with current or previous criminal legal involvement at Worcester Recovery Center and Hospital (WRCH). The study has three aims: 1. Evaluate feasibility, fidelity, and patient satisfaction during the implementation of the CLCO-9 group treatment at WRCH 2. Evaluate CLCO-9's effectiveness on improving patient's self-reported mental health, and behavioral indicators of mental health and risk factors for legal involvement 3. Explore changes in WRCH clinicians' knowledge and attitudes about treating risk factors for criminal legal involvement. To test these aims, the research team will employ a two-phase study. In the first phase, the researchers will implement the intervention and make necessary adjustments to maximize the success of the implementation. In the second phase, the researchers will evaluate the treatment program's effectiveness in producing change from pre- to post-treatment. All patient participants in this study will receive the intervention. The projected sample size is about 20 treatment completers and 4 to 8 group leaders.

Waitlist Available
Has No Placebo

Worcester Recovery Center and Hospital

Faith Scanlon, PhD

Have you considered Trilafon clinical trials?

We made a collection of clinical trials featuring Trilafon, we think they might fit your search criteria.
Go to Trials